Filing Flows › Viridian Therapeutics (VRDN) › Q4 2025
Viridian Therapeutics (VRDN) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Viridian Therapeutics (VRDN) reported revenue of $132K for the fourth quarter 2025 (Q4 2025), +83% from a year earlier and -100% from the quarter before.
Viridian Therapeutics, Q4 2025: revenue $132K (+83% year over year), net loss $120M, operating cash flow −$23.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $132K | -100% | +83% |
| Operating profit | −$123M | — | — |
| Net earnings | −$120M | — | — |
| Operating cash flow | −$23.8M | — | — |
What changed
Revenue was $132K in Q4 2025, up 83% year over year and down 100% from the previous quarter.
Operating costs exceeded revenue by $122.7M, an operating margin of -92991.7%. Total costs grew 40% against revenue growth of 83%. The fastest-growing cost line was Research & development (+24%). The quarter ended with a net loss of $120.4M, wider than the previous quarter's $34.6M loss.
Operating cash flow was −$23.8M. Non-cash charges added back $120K of depreciation and amortization and $12.0M of share-based compensation. Working capital and other items added $84.5M. Capital expenditures of $240K exceeded it, leaving free cash flow of −$24.0M.
Questions
What was Viridian Therapeutics' revenue in the fourth quarter 2025?
Viridian Therapeutics (VRDN) reported revenue of $132K for the fourth quarter 2025 (Q4 2025), +83% from a year earlier and -100% from the quarter before.